



To: Pillartree Limited
2 Grand Canal Square
Dublin 2
D021 A342
Ireland

To: Amgen Inc.
One Amgen Center Drive
Thousand Oaks
CA 91320-1799
USA

23 January 2023

Recommended acquisition of Horizon Therapeutics plc by Pillartree Limited, a wholly owned subsidiary of Amgen Inc. (the "Offer")

Dear Sir or Madam,

We refer to the Proxy Statement to be issued by Amgen Inc. and Horizon Therapeutics plc on or around 23 January 2023 in connection with the Offer, a draft copy of which is attached to this letter for the purposes of identification (the "**Proxy Statement**").

We hereby consent to the issue of the Proxy Statement with the inclusion of the references to our name in the form and context in which they appear.

Yours faithfully

A handwritten signature in black ink, appearing to read "T. J. Bernard", written over a horizontal line.

For and on behalf of
CITIGROUP GLOBAL MARKETS INC.